Flick Gocke Schaumburg advises KKR on its investment in Coriolis Pharma

Flick Gocke Schaumburg has advised KKR Health Care Strategic Growth Fund II on its investment in German biopharmaceutical research and development company Coriolis Pharma.

Advisor KKR: Flick Gocke Schaumburg

Matthias Full (Lead), Corina Hackbarth; Associates: Franz-Joseph Reisner (all M&A/Tax)

Services provided include all tax aspects of the transaction (including tax due diligence, structuring, and tax input on the purchase agreement) in cooperation with FGS partner firm Alvarez & Marsal Tax LLP with a London team led by Hiral Bhatt (M&A/Tax).

Coriolis Pharma is a global service provider and world leader in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines.
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach.

As part of the transaction, Coriolis Pharma will enter into a strategic growth partnership with Frontier Biosolutions, a global pharmaceutical services platform newly formed by KKR and Flerie Invest AB. 

KKR's investment will enable Coriolis Pharma to embark on the next phase of growth in its core business, expand its portfolio of services along the value chain, strengthen its global footprint and continue to integrate AI-based technologies. <<<